Effects of short-time (3 months) tibolone treatment on bone turnover in postmenopausal women

Archives of Gynecology and Obstetrics

Volumn 268, Issue 2, 2003, Pages 85-87

  Fenkci, Veysel ^a,b   Yilmazer, Mehmet ^b   Fenkci, Semin ^a  

^a Afyon Kocatepe University ^*

^b AFYON KOCATEPE UNIVERSITY   (Turkey)

Author keywords

Bone markers; Tibolone

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; OSTEOCALCIN; PHOSPHORUS; TIBOLONE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; OSSIFICATION; PHOSPHATE BLOOD LEVEL; PHYSICAL EXAMINATION; POSTMENOPAUSE; URINALYSIS; VAGINA BLEEDING;

EID: 0038001528     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-002-0345-0     Document Type: Article

References (17)

1. Ettinger B, Genant HK, Cann CE (1985) Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 102:319-324
2. Hamwi A, Ganem AH, Grebe C, Kerschan-Schindl K, Preisinger E, Boschitsch E, Bieglmayer C (2001) Markers of bone turnover in postmenopausal women receiving hormone replacement therapy. Clin Chem Lab Med 39(5):414-417
3. Hart DM, Farish E, Fletcher CD, Barnes JF, Hart H, Nolan D, Spowart K (1998) Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women. Osteoporos Int 8(4):326-332
4. Kasugai Y, Ikegami A, Matsuo K, Ohashi M, Sukamoto T, Hosoi T, Ouchi Y, Orimo H (1998) Effects of tibolone (Org OD14) treatment for 3 months on ovariectomy-induced osteopenia in 8-month-old rats on a low-calcium diet: preventive testing for 3 months. Bone 22(2):119-124
5. Lindsay R, Aitken JM, Anderson JB, Hart DM, MacDonald EB, Clarke AC (1976) Long-term prevention of postmenopausal osteoporosis by oestrogen: Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1:1038-1041
6. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J (1999) The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 14(9):1583-1595
7. Milner M, Harrison RF, Gilligan E, Kelly A (2000) Bone density changes during two years treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women. Menopause 7(5):327-333
8. Pavlov PW, Ginsburg J, Kicovic PM, van der Schaaf DB, Prelevic G, Bennink HJ (1999) Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Gynecol Endocrinol 13(4):230-237
9. Peichl P, Griesmacher A, Muller MM, Marteau R, Kumpan W, Broll H (2000) Serum osteocalcin and urinary crosslaps are suitable markers of bone turnover in response to short-term hormone replacement therapy. Gynecol Endocrinol 14(5):374-381
10. Peris P, Alvarez L, Monegal A, Guanabens N, Duran M, Pons F, Martinez de Osaba MJ, Echevarria M, Ballesta AM, Munoz-Gomez J (1999) Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Bone 25(3):349-353
11. Prestwood KM, Kenny AM, Unson C, Kulldorff M (2000) The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab 85(12):4462-4469
12. Reginster JY, Agnusdei D, Gennari C, Kicovic PM (1999) Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women. Gynecol Endocrinol 13(5):361-368
13. Rymer J, Robinson J, Fogelman I (2001) Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporos Int 12(6):478-483
14. Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, Lindsay R (1993) Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 8(7):881-889
15. Studd J, Arnala I, Kicovic PM, Zamblera D, Kroger H, Holland N (1998) A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 92[4 Pt 1]:574-579
16. Watts NB, Nolan JC, Brennan JJ, Yang HM; ESTRATAB/Osteoporosis Study Group (2000) Esterified estrogen therapy in postmenopausal women. Relationships of bone marker changes and plasma estradiol to BMD changes: a two-year study. Menopause 7(6):375-382
17. Yoshitake K, Yokota K, Kasugai Y, Kagawa M, Sukamoto T, Nakamura T (1999) Effects of 16 weeks of treatment with tibolone on bone mass and bone mechanical and histomorphometric indices in mature ovariectomized rats with established osteopenia on a low-calcium diet. Bone 25(3):311-319